What Happened

The FDA granted 510(k) clearance to Miami-based VertigoDx for its SmartVertigo vestibular assessment system. The portable device combines a smartphone, a light-blocking headset, and software that tracks involuntary eye movements (nystagmus) to differentiate inner ear issues like benign paroxysmal positional vertigo (BPPV) from central nervous system disorders. The system has been used on more than 1,200 patients over the past three years, replacing traditional infrared video-oculography with color video that captures subtler findings.

Who Is Affected

VertigoDx, a medtech startup founded by brothers Trevor Meyerowitz (CMO) and Stephen Meyerowitz (CTO) and led by CEO Paul Louis, is the direct beneficiary of this clearance. The SmartVertigo is a prescription point-of-care platform targeting clinicians diagnosing vertigo and dizziness. Competitor Otolith Labs, backed by Mark Cuban, previously received breakthrough device designation for a noninvasive treatment for chronic vertigo symptoms, but this clearance turns VertigoDx into a commercial-ready diagnostic player.

Market Impact

• Opens the US market for a portable diagnostic system that replaces expensive, immobile infrared workstations and specialist referrals.
• VertigoDx can now scale sales to ENT clinics, primary care practices, and emergency departments seeking objective, on-site vertigo diagnosis.
• The system’s AI algorithms and color video capability provide a differentiation point over existing solutions, potentially accelerating adoption.

What to Watch

VertigoDx’s commercialization strategy—how it builds distribution partnerships, hires sales teams, and targets key accounts in the dizziness diagnostic space. Also watch for competitive responses, especially from Otolith Labs, which may pivot from treatment to diagnostic integration. The company’s next steps after 510(k) clearance will signal its readiness to scale operations and revenue.

Related coverage

• FDA Grants 510(k) Clearance to Click Therapeutics' Motivista for Schizophrenia
• FDA approves AbbVie's Parkinson's drug Juvmo (tavapadon) developed from UVA research
• FDA approves Lilly's Jaypirca as first noncovalent BTK inhibitor for first-line CLL/SLL
• FDA approves Mirum's oral drug Atebrioz for rare disease FOP